Sartorius combines biotech division with Stedim

Germany's Sartorius has struck a deal to combine its biotech division with Stedim Biosystems. Sartorius emerges as the majority owner of a combined company called Sartorius Stedim Biotechnology. France's Stedim claims bragging rights as the pioneer for disposable bag systems for biopharmaceutical applications. Stedim also has a product segment consisting of door systems for aseptic transfer technology and a freeze-thaw technology.

"This transaction significantly accelerates our strategy to offer customers fully integrated solutions for next-generation biopharmaceutical manufacturing," Joachim Kreuzburg, CEO and chairman of Sartorius' executive board. "Our two companies' product array, technology platforms, and regional strengths are highly complementary. Therefore, we are a perfect match."

- see this release on the merger

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.